Olema Pharmaceuticals Reports Third Quarter GAAP EPS Miss
Olema Pharmaceuticals (OLMA) reported third-quarter earnings that fell short of market expectations, posting a GAAP Earnings Per Share (EPS) of -$0.73. This result represents a $0.10 miss compared to analyst estimates. The company's recent performance comes amid significant clinical developments and leadership changes, including the appointment of Jason O’Byrne as CFO. Investors are closely monitoring upcoming data readouts for its oncology pipeline, specifically regarding breast cancer therapies.
Topics: biotechnology earnings report EPS miss oncology
Read the full article at Seeking Alpha
Part of the story Septerna, Inc. Reports Third Quarter GAAP EPS of -$0.57 and Revenue of $18.88M (3 articles)